Central nervous system involvement in Sjögren's syndrome: Unusual, but not unremarkable-clinical, serological characteristics and outcomes in a large cohort of Italian patients

Rheumatology

Volumn 49, Issue 8, 2010, Pages 1540-1549

  Massara, Alfonso ^a   Bonazza, Saras ^a   Castellino, Gabriella ^a   Caniatti, Luisa ^b   Trotta, Francesco ^a   Borrelli, Massimo ^b   Feggi, Luciano ^b   Govoni, Marcello ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Central nervous system; Clinical findings; Extraglandular manifestations; Instrumental evaluation; Neurological involvement; Primary Sj gren's syndrome

Indexed keywords

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DISEASE DURATION; FEMALE; HUMAN; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGICAL COMPLICATION; OPTIC NEURITIS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SJOEGREN SYNDROME;

ADULT; AGED; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM DISEASES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; ITALY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME; TIME FACTORS;

EID: 77954696400     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq111     Document Type: Article

References (60)

1. Binard A, Devauchelle-Pensec V, Fautrel B, Jousse S, Youinou P, Saraux A. Epidemiology of Sjögren's syn-drome: where are we now? Clin Exp Rheumatol 2007;25:1-4.
2. Fox RI. Sjogren's syndrome. Lancet 2005;366:321-31.
3. Soliotis FC, Mavragani CP, Moutsopoulos HM. Central nervous system involvement in Sjogren's syndrome. Ann Rheum Dis 2004;63:616-20.
4. Govoni M, Padovan M, Rizzo N, Trotta F. CNS involve-ment in primary Sjogren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach. CNS Drugs 2001;15:597-607.
5. Govoni M, Bajocchi G, Rizzo N et al. Neurological involvement in primary Sjogren's syndrome: clinical and instrumental evaluation in a cohort of Italian patients. Clin Rheumatol 1999;18:99-303.
6. Vitali C, Bombardieri S, Jonsson R et al. European Study Group on Classification Criteria for Sjogren's syndrome. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
7. ACR ad hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
8. Alarcón GS, Williams GV, Singer JZ et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol 1991; 18:1332-9.
9. Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood Pressure (JNC-V1). Sixth report. Arch Intern Med 1997;157: 2413-46.
10. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
12. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
13. Horbach DA, Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antipho-spholipid antibodies. Thromb Haemost 1996;76:916-24.
14. Castellino G, Padovan M, Bortoluzzi A et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology 2008;47:319-23.
15. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005;58:840-6.
16. Garcia-Carrasco M, Ramos-Casals M, Rosas J et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002;81:270-80.
17. Lafitte C, Amoura Z, Cacoub P et al. Neurological complications of primary Sjogren's syndrome. J Neurol 2001;248:577-84.
18. Moll JW, Markusse HM, Pijnenburg JJ, Vecht CJ, Henzen-Logmans SC. Antineuronal antibodies in patients with neurologic complications of primary Sjogren's syndrome. Neurology 1993;43:2574-81.
19. Escudero D, Latorre P, Codina M, Coll-Canti J, Coll J. Central nervous system disease in Sjogren's syndrome. Ann Med Interne 1995;146:239-42.
20. De Seze J, Delalande S, Vermersch P. Neurological manifestations in Sjogren syndrome. Rev Med Interne 2005;26:624-36.
21. Delalande S, de Seze J, Fauchais AL et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine 2004;83:280-91.
22. Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjogren's syndrome. Medicine 1982;61:247-57.
23. Mellgren SI, Conn DL, Stevens JC, Dyck PJ. Peripheral neuropathy in primary Sjogren's syndrome. Neurology 1989;39:390-4.
24. Ioannidis JP, Moutsopoulos HM. Sjogren's syndrome: too many associations, too limited evidence. The enigmatic example of CNS involvement. Semin Arthritis Rheum 1999;29:1-3.
25. Awad IA, Spetzler RF, Hodak JA, Awad CA, Carey R. Incidental subcortical lesions identified on magnetic resonance imaging in the elderly. I. Correlation with age and cerebrovascular risk factors. Stroke 1986;17:1084-9.
26. Ovbiagele B, Saver JL. Cerebral white matter hyperintensities on MRI: current concepts and therapeutic implications. Cerebrovasc Dis 2006;22:83-90.
27. Coates T, Slavotinek JP, Rischmueller M et al. Cerebral white matter lesions in primary Sjogren's syndrome: a controlled study. J Rheumatol 1999;26:1301-5.
28. Pierot L, Sauve C, Leger JM et al. Asymptomatic cerebral involvement in Sjogren's syndrome: MRI findings of 15 cases. Neuroradiology 1993;35:378-80.
29. de Leeuw FE, de Groot JC, Achten E et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatr 2001;70:9-14.
30. Morgen K, McFarland HF, Pillemer SR. Central nervous system disease in primary Sjogren's syndrome: the role of magnetic resonance imaging. Semin Arthritis Rheum 2004;34:623-30.
31. Mataro M, Escudero D, Ariza M et al. Magnetic resonance abnormalities associated with cognitive dysfunction in primary Sjogren syndrome. J Neurol 2003;250:1070-6.
32. Alexander EL, Beall SS, Gordon B et al. Magnetic resonance imaging of cerebral lesions in patients with the Sjogren syndrome. Ann Intern Med 1988;108:815-23.
33. Alexander EL. Neurologic disease in Sjogren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. A clinical review and update of immunopathogenesis. Rheum Dis Clin North Am 1993;19:869-908.
34. Noseworthy JH, Bass BH, Vandervoort MK et al. The prevalence of primary Sjogren's syndrome in a multiple sclerosis population. Ann Neurol 1989;25:95-8.
35. Miró J, Peña-Sagredo JL, Berciano J, Insua S, Leno C, Velarde R. Prevalence of primary Sjogren's syndrome in patients with MS. Ann Neurol 1990;27:582-4.
36. Metz LM, Seland TP, Fritzler MJ. An analysis of the fre-quency of Sjogren's syndrome in a population of multiple sclerosis patients. J Clin Lab Immunol 1989;30:121-5.
37. Harboe E, Tjensvoll AB, Maroni S et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and primary Sjögren syndrome: a comparative population-based study. Ann Rheum Dis 2009;68:1541-6.
38. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 1998;55:517-21.
39. de Andrés C, Guillem A, Rodríguez-Mahou M, López Longo FJ. Frequency and significance of anti-Ro (SS-A) antibodies in multiple sclerosis patients. Acta Neurol Scand 2001;104:83-7.
40. Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE. Primary Sjogren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 1986;104:323-30.
41. Alexander E. Central nervous system disease in Sjogren's syndrome. New insights into immunopathogenesis. Rheum Dis Clin North Am 1992;18:637-72.
42. de Seze J, Dubucquoi S, Fauchais AL et al. Alpha-fodrin autoantibodies in the differential diagnosis of MS and Sjogren syndrome. Neurology 2003;61:268-9.
43. de Seze J, Dubucquoi S, Fauchais AL et al. Autoantibodies against alpha-fodrin in Sjogren's syndrome with neurological manifestations. J Rheumatol 2004;31:500-3.
44. Anaya JM, Villa LA, Restrepo L, Molina JF, Mantilla RD, Vargas S. Central nervous system compromise in primary Sjogren's syndrome. J Clin Rheumatol 2002;8:189-96.
45. Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatr 2006;77:290-5.
46. Bourahoui A, De Seze J, Guttierez R et al. CSF isoelec-trofocusing in a large cohort of MS and other neurological diseases. Eur J Neurol 2004;11:525-9.
47. Tsai KY, Tsai CP, Liao N. Sjogren's syndrome with central nervous system involvement presenting as multiple sclerosis with failure response to beta-interferon. Eur Neurol 2001;45:59-60.
48. De Santi L, Costantini MC, Annunziata P. Long time interval between multiple sclerosis onset and occurrence of primary Sjogren's syndrome in a woman treated with interferon-beta. Acta Neurol Scand 2005;112:194-6.
49. Alexander EL, Ranzenbach MR, Kumar AJ et al. Anti-Ro (SS-A) autoantibodies in central nervous system disease associated with Sjogren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology 1994;44:899-908.
50. Megevand P, Chizzolini C, Chofflon M, Roux-Lombard P, Lalive PH, Picard F. Cerebrospinal fluid anti-SSA autoantibodies in primary Sjogren's syndrome with central nervous system involvement. Eur Neurol 2007;57:166-71.
51. Sanders ME, Alexander EL, Koski CL, Frank MM, Joiner KA. Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus. J Immunol 1987;138:2095-9.
52. Alexander EL, Lijewski JE, Jerdan MS, Alexander GE. Evidence of an immunopathogenic basis for central nervous system disease in primary Sjogren's syndrome. Arthritis Rheum 1986;29:1223-31.
53. Alexander EL, Provost TT, Sanders ME, Frank MM, Joiner KA. Serum complement activation in central nervous system disease in Sjogren's syndrome. Am J Med 1988;85:513-8.
54. Ramos-Casals M, Brito-Zeron P, Yague J et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology 2005;44:89-94.
55. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthritis Rheum 2002;46:741-7.
56. Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. Arthritis Rheum 2004;50:1262-9.
57. Pennec YL, Magadur G, Jouquan J, Youinou P. Serial measurements of anticardiolipin antibodies in primary Sjogren's syndrome. Clin Exp Rheumatol 1991;9:165-7.
58. Asherson RA, Fei HM, Staub HL, Khamashta MA, Hughes GR, Fox RI. Antiphospholipid antibodies and HLA associations in primary Sjogren's syndrome. Ann Rheum Dis 1992;51:495-8.
59. Cervera R, Garcia-Carrasco M, Font J et al. Antiphospholipid antibodies in primary Sjogren's syn-drome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol 1997;15:361-5.
60. Ramos-Casals M, Brito-Zerón P, Sisó A et al. High prevalence of serum metabolic alterations in primary Sjögren's syndrome: influence on clinical and immunological expression. J Rheumatol 2007;34:754-61.